首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1473886

全球人畜共通傳染病治療市場規模、佔有率、成長分析、依類型、依病原體、依藥物類別、依給藥途徑、依最終用戶、依配銷通路- 2024-2031 年行業預測

Global Zoonotic Disease Treatment Market Size, Share, Growth Analysis, By Types, By Causative Agent, By Drug Class, By Route of Administration, By End-Users, By Distribution Channel - Industry Forecast 2024-2031

出版日期: 2024年04月27日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年，全球人畜共通傳染病治療市場規模為369.1億美元，預計將從2023年的391.6億美元成長到2031年的628.9億美元，預測期內（2024-2031年）複合年成長率為6.1% 。

美國疾病管制與預防中心 (CDC) 預計，每年將有數以萬計的美國人罹患由動物傳播的疾病。此外，城市化和人口快速成長預計將在未來加劇人畜共患病。市場受到城市地區衛生條件不佳的影響，促成了這一趨勢。此外，對動物性蛋白質的需求不斷成長可能會導致動物脂肪的消費增加，進一步推動治療人畜共通傳染病的市場。此外，由於數以百萬計的家庭飼養寵物進行陪伴和娛樂，因此接觸動物攜帶的疾病的風險也增加了。然而，儘管養寵物有好處，但許多發展中國家對人畜共通傳染病缺乏認知，與研發相關的高成本可能會阻礙市場成長。儘管如此，全球市場預計將受益於未來幾年為滿足特定動物保健需求而推出的創新藥物。

美國疾病管制與預防中心 (CDC) 預計，每年將有數以萬計的美國人罹患由動物傳播的疾病。此外，城市化和人口快速成長預計將在未來加劇人畜共患病。市場受到城市地區衛生條件不佳的影響，促成了這一趨勢。此外，對動物性蛋白質的需求不斷成長可能會促使動物脂肪的消費增加，進一步推動治療人畜共通傳染病的市場。此外，由於數以百萬計的家庭飼養寵物進行陪伴和娛樂，因此接觸動物攜帶的疾病的風險也增加了。然而，儘管養寵物有好處，但許多發展中國家對人畜共通傳染病缺乏認知，與研發相關的高成本可能會阻礙市場成長。儘管如此，全球市場預計將受益於未來幾年為滿足特定動物保健需求而推出的創新藥物。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 歐洲其他地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 拉丁美洲其他地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- MEA 的其餘部分

競爭格局

前 5 名企業比較
2023 年關鍵參與者的市場定位
主要市場參與者所採取的策略
最佳制勝策略
近期市集活動
主要公司市佔率 (%), 2023

主要公司簡介

Zoetis Inc.
Merck & Co., Inc.
Sanofi SA
Boehringer Ingelheim International GmbH
Eli Lilly and Company
Bayer AG
Virbac
Vetoquinol SA
Ceva Sante Animale
Heska Corporation
In February 2021, Johnson & Johnson announced the success of its COVID-19 vaccine, which has also been authorized for emergency use in many countries. The company is also developing a vaccine for Zika virus and a vaccine for respiratory syncytial virus (RSV)
In June 2020, Merck, known as MSD outside the United States, Canada, announced the completion of the acquisition of Themis, a privately-held company focused on vaccines and immune-modulation therapies for infectious diseases and cancer. The US Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, and Merck has received merger control clearance from the Austrian Federal Competition Authority. Themis is now a wholly-owned subsidiary of Merck.

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 歐洲其他地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 拉丁美洲其他地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- MEA 的其餘部分

競爭格局

前 5 名玩家比較
2023 年關鍵參與者的市場定位
主要市場參與者所採取的策略
最佳制勝策略
近期市集活動
主要公司市佔率 (%), 2023

主要公司簡介

Zoetis Inc.
Merck & Co., Inc.
Sanofi SA
Boehringer Ingelheim International GmbH
Eli Lilly and Company
Bayer AG
Virbac
Vetoquinol SA
Ceva Sante Animale
Heska Corporation
In February 2021, Johnson & Johnson announced the success of its COVID-19 vaccine, which has also been authorized for emergency use in many countries. The company is also developing a vaccine for Zika virus and a vaccine for respiratory syncytial virus (RSV)
In June 2020, Merck, known as MSD outside the United States, Canada, announced the completion of the acquisition of Themis, a privately-held company focused on vaccines and immune-modulation therapies for infectious diseases and cancer. The US Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, and Merck has received merger control clearance from the Austrian Federal Competition Authority. Themis is now a wholly-owned subsidiary of Merck.

簡介目錄

Product Code: SQMIG35I2117

Global zoonotic disease treatment market size was valued at USD 36.91 billion in 2022 and is poised to grow from USD 39.16 billion in 2023 to USD 62.89 billion by 2031, at a CAGR of 6.1% during the forecast period (2024-2031).

The Centres for Disease Control and Prevention (CDC) projects that tens of thousands of Americans will suffer from diseases transmitted from animals annually. Additionally, urbanization and rapid population growth are expected to exacerbate zoonotic diseases in the future. The market is influenced by poor sanitation rates in urban areas, which contribute to this trend. Moreover, the growing demand for animal proteins is likely to lead to increased consumption of animal fats, further driving the market for treating zoonotic diseases. Additionally, with millions of households owning pets for companionship and entertainment, there is a heightened risk of exposure to diseases carried by animals. However, despite the benefits of pet ownership, there is a lack of awareness about zoonotic diseases in many developing countries, and the high costs associated with research and development could impede market growth. Nonetheless, the global market is expected to benefit from the introduction of innovative medications to address specific animal healthcare needs in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the global zoonotic disease treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Zoonotic Disease Treatment Market Segmental Analysis

Global zoonotic disease treatment market is segmented based on types, causative agent, drug class, and route of administration, end-users, distribution channel and region. By type, the market is segmented into rabies, tuberculosis, malaria, leishmaniasis, ebola virus disease, and others. By causative agent, the market is segmented into bacteria, virus, nematodes, rodents, ticks, and others. By drug class, the market is segmented into anti-fungal, anti-bacterial, antibiotics, and others. By route of administration, the market is segmented into oral, topical and others. By end-users, the market is segmented into hospitals, specialty clinics, homecare and others. By distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, online pharmacy and others. By region, the market is segmented into North America, Europe, Asia-Pacific, South America, and MEA.

Drivers of the Global Zoonotic Disease Treatment Market

The zoonotic disease treatment market is being propelled by various factors, including the growing prevalence of zoonotic diseases and heightened awareness regarding their transmission. Additionally, the continuous development of novel and efficient treatments, coupled with government initiatives, contributes to market growth. Furthermore, advancements in technology and heightened investment in research and development are driving forces behind the market's expansion.

Restraints in the Global Zoonotic Disease Treatment Market

While the zoonotic disease treatment market holds considerable growth prospects, several factors may impede its expansion. These include challenges such as the limited availability of effective treatment options, high treatment costs, and insufficient investment in research and development. Additionally, the introduction of generic medications and the expiration of patents on branded drugs are expected to decelerate market growth. Furthermore, the market may encounter difficulties due to a shortage of skilled healthcare professionals and inadequate healthcare infrastructure in developing countries. Moreover, the high capital expenditure required for research and development, coupled with low awareness levels, could constrain the market's growth rate.

Market Trends of the Global Zoonotic Disease Treatment Market

The adoption of the one health approach, which underscores the interconnectedness of human, animal, and environmental health, is gaining traction in the zoonotic disease treatment market. Companies are actively developing treatments that not only focus on human health but also aim to enhance animal health and prevent the transmission of zoonotic diseases. In this evolving landscape, innovative treatments like gene therapy, immunotherapy, and targeted therapies are being developed, offering novel options for patients and paving the way for market expansion.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Zoonotic Disease Treatment Market by Types

Market Overview
Rabies
tuberculosis
malaria
leishmaniasis
Ebola virus disease
and others

Global Zoonotic Disease Treatment Market by Causative Agent

Market Overview
Bacteria
virus
nematode
rodents
ticks
and others

Global Zoonotic Disease Treatment Market by Drug Class

Market Overview
Anti-Fungal
Anti-Bacterial
Antibiotics
and Others

Global Zoonotic Disease Treatment Market by Route of Administration

Market Overview
Oral
Topical and Others.

Global Zoonotic Disease Treatment Market by End-Users

Market Overview
Hospitals
Specialty Clinics
Homecare and Others

Global Zoonotic Disease Treatment Market by Distribution Channel

Market Overview
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy and Others

Global Zoonotic Disease Treatment Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Zoetis Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Virbac
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vetoquinol S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ceva Sante Animale
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Heska Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
In February 2021, Johnson & Johnson announced the success of its COVID-19 vaccine, which has also been authorized for emergency use in many countries. The company is also developing a vaccine for Zika virus and a vaccine for respiratory syncytial virus (RSV)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
In June 2020, Merck, known as MSD outside the United States and Canada, announced the completion of the acquisition of Themis, a privately-held company focused on vaccines and immune-modulation therapies for infectious diseases and cancer. The U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and Merck has received merger control clearance from the Austrian Federal Competition Authority. Themis is now a wholly-owned subsidiary of Merck.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments